Survodutide
Research profile · How we handle evidence
Survodutide is an investigational drug candidate that targets GLP-1 and glucagon receptors (a dual-agonist approach) and is being studied for metabolic diseases, including conditions related to excess liver fat and obesity.
Evidence Score
Moderate confidence
Category
Therapeutic area
Standard Dose
Once weekly
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Monitor closely
Overview
Survodutide is in human clinical trials and is designed to influence appetite and metabolism through GLP-1/glucagon receptor signaling. Research uses it as a dual-agonist strategy: in some studies, it has been associated with improvements in liver fat and weight-related outcomes. This page is for research library and educational support, not personal medical advice. As with any investigational compound, outcomes and side effects can vary across people, and it should only be used in the context of qualified medical supervision or a registered clinical trial.
Mechanism of Action
Survodutide is in human clinical trials and is designed to influence appetite and metabolism through GLP-1/glucagon receptor signaling. Research uses it as a dual-agonist strategy: in some studies, it has been associated with improvements in liver fat and weight-related outcomes. This page is for research library and educational support, not personal medical advice. As with any investigational compound, outcomes and side effects can vary across people, and it should only be used in the context of qualified medical supervision or a registered clinical trial.
Benefits
- Dual receptor activity (GLP-1 + glucagon signaling)
Side Effects
- Nausea and GI upset are commonly reported class effects in GLP-1–related therapies
- Injection-site reactions can occur
Contraindications
- Pregnancy or breastfeeding women (use only with clinician guidance)
- History of medullary thyroid cancer (important precaution in GLP-1–related drug classes)
Structure & Sequence
Verified structure
Survodutide
Sequence illustration backed by PubChem match.
- Amino Acid Sequence
- 29-amino-acid acylated glucagon analog, dual GCGR/GLP-1R agonist
- Molecular Weight
- 4,359.73 Da
- Chemical Formula
- C192H289N47O61
- CAS Number
- 2805997-46-8
- InChIKey
- MEDXQFAHWBMVIM-YIUAJOCSSA-N
Stack & Route Context
Stacks with
No entries listed.
Administration
Subcutaneous
Research Status
Phase 2 clinical trials for metabolic disease/obesity-related endpoints
Approval Status
Phase2
Sports Legal
Permitted
References
- 1View source
PubMed: Survodutide phase 2 trial in MASH and fibrosis (NEJM publication)
- 2View source
ClinicalTrials.gov: NCT04771273 (Survodutide in MASH and fibrosis)
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.